Experimental autoimmune encephalomyelitis (EAE) is a T cell- mediated inflammatory demyelinating disease of the CNS that serves as a model for human multiple sclerosis. In the SJL/J mice, a relapsing-remitting form of EAE (R-EAE) is induced following active immunization with proteolipid protein (PLP), myelin basic protein (MBP), or the immunodominant epitopes on these molecules (PLP139-151 or MBP84-104) or following adoptive transfer of peptide- specific Th1 cells. Based on the relapsing-remitting course of the disease, along with the finding that Date Released: 05/15/1997 disease progression (relapses) in these peptide induced R-EAE models are due primarily to the recruitment of T cell responses against non- crossreactive endogenous myelin epitopes on the same or different myelin proteins (intermolecular or intramolecular epitope spreading), it is hypothesized that disease remission results from specific form(s) of immunoregulation.
Specific Aim 1 will continue studies from the previous funding period to test several non-mutually exculsive hypotheses by which responses to disease initiating epitopes may be down-regulated leading to disease remission: 1) potential switching of CNS cytokines from pro-inflammatory to anti-inflammatory; 2)CTLA- 4-mediated anergy and/or Fas/FasL-mediated apoptosis of disease initiating Th1 cells; 3) activation of antigen- or TCR-specific regulatory T cell populations in response to disease-initiating T cells.
Specific Aim 2 will elucidate the mechanisms responsible for downregulation of disease following extrinsic induction of antigen-specific peripheral tolerance induced by the i.v. injection of protein/peptide-pulsed, ethylene carbodiimide (ECDI)-fixed antigen presenting cells (Ag-SP).
Specific Aim 2 will further test the hypothesis that unresponsiveness induced by the i.v. injection of Ag-SP is primarily mediated by clonal anergy or encephalitogenic Th1 cells. The effects of tolerance at varying times during the disease process on the activation state, CNS homing properties, and cytokine expression patterns of effector Th1 cells will be determined. In addition, in vitro experiments utilizing encephalitogenic Th1 clones and in vivo experiments using TCR transgenic mouse systems will be employed to directly assess the relative contributions of clonal anergy vs. deletion to the unresponsive state. These studies would enhance our understanding of both intrinsic mechanisms of spontaneous disease remission, an delineate the molecular mechanisms of a highly efficient extrinsic method of inducing peripheral immune tolerance proven effective for the treatment of pre-existing autoimmune disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS026543-12
Application #
2891730
Study Section
Special Emphasis Panel (ZRG1-NEUC (01))
Program Officer
Kerza-Kwiatecki, a P
Project Start
1988-07-01
Project End
2001-06-30
Budget Start
1999-07-01
Budget End
2000-06-30
Support Year
12
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Northwestern University at Chicago
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Prasad, Suchitra; Neef, Tobias; Xu, Dan et al. (2018) Tolerogenic Ag-PLG nanoparticles induce tregs to suppress activated diabetogenic CD4 and CD8 T cells. J Autoimmun 89:112-124
Neef, Tobias; Miller, Stephen D (2017) Tolerogenic Nanoparticles to Treat Islet Autoimmunity. Curr Diab Rep 17:84
Pearson, Ryan M; Casey, Liam M; Hughes, Kevin R et al. (2017) Controlled Delivery of Single or Multiple Antigens in Tolerogenic Nanoparticles Using Peptide-Polymer Bioconjugates. Mol Ther 25:1655-1664
Ifergan, Igal; Davidson, Todd S; Kebir, Hania et al. (2017) Targeting the GM-CSF receptor for the treatment of CNS autoimmunity. J Autoimmun 84:1-11
Podojil, Joseph R; Miller, Stephen D (2017) Potential targeting of B7-H4 for the treatment of cancer. Immunol Rev 276:40-51
Kuo, Robert; Saito, Eiji; Miller, Stephen D et al. (2017) Peptide-Conjugated Nanoparticles Reduce Positive Co-stimulatory Expression and T Cell Activity to Induce Tolerance. Mol Ther 25:1676-1685
Pearson, Ryan M; Casey, Liam M; Hughes, Kevin R et al. (2017) In vivo reprogramming of immune cells: Technologies for induction of antigen-specific tolerance. Adv Drug Deliv Rev 114:240-255
Kang, Hee Kap; Wang, Shusen; Dangi, Anil et al. (2017) Differential Role of B Cells and IL-17 Versus IFN-? During Early and Late Rejection of Pig Islet Xenografts in Mice. Transplantation 101:1801-1810
Jeong, Su Ji; Cooper, John G; Ifergan, Igal et al. (2017) Intravenous immune-modifying nanoparticles as a therapy for spinal cord injury in mice. Neurobiol Dis 108:73-82
Edwards, Rebecca G; Kopp, Sarah J; Ifergan, Igal et al. (2017) Murine Corneal Inflammation and Nerve Damage After Infection With HSV-1 Are Promoted by HVEM and Ameliorated by Immune-Modifying Nanoparticle Therapy. Invest Ophthalmol Vis Sci 58:282-291

Showing the most recent 10 out of 150 publications